Philip Cohen has been awarded the Bristol-Myers Squibb Foundation Distinguished Achievement Award in Metabolic Research for his work on diabetes.
The award recognises his leading role in identifying how insulin accelerates the conversion of glucose into glycogen, the major storage form of glucose in the body.
Philip is the first non-American to receive this award, and will be presented with the cash prize of $50,000 and a commemorative silver medallion at a gala dinner to be held in his honour on 16 October in New York. Philip will present a lecture at the Bristol Myer Squibb Facility in New Jersey on 17 October.
The Bristol-Myers Squibb Unrestricted Biomedical Research Grants Program that provides the Metabolic Award was initiated in 1977. The programme is celebrating its 25th year, reaching the milestone of $100 million in no-strings-attached funding in six biomedical research areas, including cancer cardiovascular, infectious diseases, metabolic diseases, neuroscience and nutrition.
The award recognises his leading role in identifying how insulin accelerates the conversion of glucose into glycogen, the major storage form of glucose in the body.
Philip is the first non-American to receive this award, and will be presented with the cash prize of $50,000 and a commemorative silver medallion at a gala dinner to be held in his honour on 16 October in New York. Philip will present a lecture at the Bristol Myer Squibb Facility in New Jersey on 17 October.
The Bristol-Myers Squibb Unrestricted Biomedical Research Grants Program that provides the Metabolic Award was initiated in 1977. The programme is celebrating its 25th year, reaching the milestone of $100 million in no-strings-attached funding in six biomedical research areas, including cancer cardiovascular, infectious diseases, metabolic diseases, neuroscience and nutrition.